Home › Compare › LTTHF vs ABBV
LTTHF yields 1.67% · ABBV yields 3.06%● Live data
📍 LTTHF pulled ahead of the other in Year 4
Combined, LTTHF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LTTHF + ABBV for your $10,000?
Learning Technologies Group plc, together with its subsidiaries, provides a range of talent and learning solutions, content, services, and digital platforms to corporate and government clients. It operates through Software & Platforms Division, Content & Services Division, GP Strategies, and Other segments. The company's software and platforms comprise Gomo, a cloud-based responsive HTML5 e-learning authoring, distribution, and video platform; Rustici Software that allow companies to create, distribute, manage, and play e-learning-compliant content; PeopleFluent, an integrated talent management and learning solution; and Affirmity, which offers analysis, consulting, training, and software to optimize affirmative action and diversity, and inclusion programs. Its software and platforms also include Watershed, a SaaS learning analytics platform; VectorVMS that delivers software and services for businesses to optimize their contingent workforce programmes; Breezy HR, a recruiting platform and applicant tracking system; Instilled, a structured corporate learning experience platform; Open LMS that helps organizations and institutions to deliver learning experiences; and Bridge, a learning and performance platform. In addition, the company engages in the mobile e-learning and e-learning interoperability businesses; operation of employee benefit trust; and provision of video distribution software. The company operates in the United Kingdom, the United States, the Asia Pacific, Mainland Europe, Canada, and internationally. Learning Technologies Group plc was founded in 1986 and is based in London, the United Kingdom.
Full LTTHF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.